News
Immunocore to co-develop IMC-C103C, a T cell redirecting bi-specific biologic, with Genentech
(Oxford, UK and Conshohocken, US, 19 November 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today announces it has entered into a new partnership with Genentech, a member of the Roche Group, to expand an existing discovery collaboration.